Extracellular vesicles with improved therapeutic capacity bancodepatentes - Banco de Patentes

The invention presents a new generation of a stromal mesenchymal cell line that overexpress HIF-1α and hTERT by genetic modification, which is cultured in the presence of secreted TNF-α, IFN-γ and IL-1β for 48 hours (EVs) with a greater therapeutic potential than those secreted by unenhanced mesenchymal stem cells (MSCs).

These new EVs exert a greater therapeutic effect and in turn allow unlimited cell growth to obtain a stable and homogeneous source of vesicles with improved therapeutic functions. By overexpression of HIF-1α, therapeutic improvement is obtained, while overexpression of hTERT generates unlimited and constant cell division. The main advantage of the invention is the combination in the use of genetic modifications with the specific culture protocol.